Fulgent Genetics Valuation
Is FLGT * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of FLGT * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: FLGT * (MX$375.22) is trading above our estimate of fair value (MX$270.72)
Significantly Below Fair Value: FLGT * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for FLGT *?
Other financial metrics that can be useful for relative valuation.
What is FLGT *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$587.11m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | n/a |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does FLGT *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 1.7x | ||
MEDICA B Médica Sur. de | 1x | 5.2% | Mex$4.1b |
OPK OPKO Health | 1.1x | 6.8% | US$846.8m |
4694 BML | 0.8x | 2.4% | JP¥114.0b |
NRC National Research | 3.7x | 33.3% | US$547.8m |
FLGT * Fulgent Genetics | 2x | 9.2% | Mex$587.1m |
Price-To-Sales vs Peers: FLGT * is expensive based on its Price-To-Sales Ratio (2x) compared to the peer average (1.7x).
Price to Earnings Ratio vs Industry
How does FLGT *'s PE Ratio compare vs other companies in the South American Healthcare Industry?
Price-To-Sales vs Industry: FLGT * is expensive based on its Price-To-Sales Ratio (2x) compared to the South American Healthcare industry average (0.8x).
Price to Sales Ratio vs Fair Ratio
What is FLGT *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 2x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate FLGT *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.